Trial Outcomes & Findings for Cadence and Intensity in Children and Adolescents (CADENCE-KIDS) (NCT NCT01989104)
NCT ID: NCT01989104
Last Updated: 2022-12-01
Results Overview
Cadence steps per minute represents an overlooked opportunity to describe the intensity of ambulatory activity.
Recruitment status
COMPLETED
Target enrollment
123 participants
Primary outcome timeframe
1 day
Results posted on
2022-12-01
Participant Flow
Participant milestones
| Measure |
Children Group 1
6-8 years of age
|
Children Group 2
9-11 years of age
|
Adolescents Group 1
12-14 years of age
|
Adolescents Group 2
15-17 years of age
|
Young Adults
18-20 years of age
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
25
|
25
|
25
|
24
|
24
|
|
Overall Study
COMPLETED
|
22
|
25
|
25
|
24
|
24
|
|
Overall Study
NOT COMPLETED
|
3
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
| Measure |
Children Group 1
6-8 years of age
|
Children Group 2
9-11 years of age
|
Adolescents Group 1
12-14 years of age
|
Adolescents Group 2
15-17 years of age
|
Young Adults
18-20 years of age
|
|---|---|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
3
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Cadence and Intensity in Children and Adolescents (CADENCE-KIDS)
Baseline characteristics by cohort
| Measure |
Children Group 1
n=22 Participants
6-8 years of age
|
Children Group 2
n=25 Participants
9-11 years of age
|
Adolescents Group 1
n=25 Participants
12-14 years of age
|
Adolescents Group 2
n=24 Participants
15-17 years of age
|
Young Adults
n=24 Participants
18-20 years of age
|
Total
n=120 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
22 Participants
n=5 Participants
|
25 Participants
n=7 Participants
|
25 Participants
n=5 Participants
|
24 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
96 Participants
n=8 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
24 Participants
n=21 Participants
|
24 Participants
n=8 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
13 Participants
n=5 Participants
|
12 Participants
n=4 Participants
|
12 Participants
n=21 Participants
|
60 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
12 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
12 Participants
n=4 Participants
|
12 Participants
n=21 Participants
|
60 Participants
n=8 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Black or African American
|
9 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
11 Participants
n=4 Participants
|
7 Participants
n=21 Participants
|
42 Participants
n=8 Participants
|
|
Race (NIH/OMB)
White
|
11 Participants
n=5 Participants
|
19 Participants
n=7 Participants
|
15 Participants
n=5 Participants
|
13 Participants
n=4 Participants
|
17 Participants
n=21 Participants
|
75 Participants
n=8 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Region of Enrollment
United States
|
22 Participants
n=5 Participants
|
25 Participants
n=7 Participants
|
25 Participants
n=5 Participants
|
24 Participants
n=4 Participants
|
24 Participants
n=21 Participants
|
120 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: 1 dayCadence steps per minute represents an overlooked opportunity to describe the intensity of ambulatory activity.
Outcome measures
| Measure |
Children Group 1
n=22 Participants
6-8 years of age
|
Children Group 2
n=25 Participants
9-11 years of age
|
Adolescents Group 1
n=25 Participants
12-14 years of age
|
Adolescents Group 2
n=24 Participants
15-17 years of age
|
Young Adults
n=24 Participants
18-20 years of age
|
|---|---|---|---|---|---|
|
Cadence - Steps Per Minute
Moderate Intensity
|
128.4 Cadence - Steps per Minute
Interval 121.7 to 134.5
|
116.5 Cadence - Steps per Minute
Interval 109.3 to 123.9
|
106.6 Cadence - Steps per Minute
Interval 102.5 to 111.0
|
101.3 Cadence - Steps per Minute
Interval 97.5 to 104.8
|
87.3 Cadence - Steps per Minute
Interval 79.4 to 95.7
|
|
Cadence - Steps Per Minute
Vigorous Intensity
|
157.7 Cadence - Steps per Minute
Interval 151.8 to 164.0
|
142.7 Cadence - Steps per Minute
Interval 134.6 to 152.8
|
129.3 Cadence - Steps per Minute
Interval 124.1 to 135.6
|
126.3 Cadence - Steps per Minute
Interval 122.9 to 129.8
|
129.9 Cadence - Steps per Minute
Interval 126.3 to 133.6
|
Adverse Events
Children Group 1
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Children Group 2
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Adolescents Group 1
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Adolescents Group 2
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Young Adults
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. William Johnson
Pennington Biomedical Research Center
Phone: 225-763-2932
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place